Brief: FDA Highlights Safety Concerns & Class I Recall for Getinge's Vasoview Hemopro Devices
Nov 15 (Reuters) - FDA:
* FDA: ALERTING HEALTH CARE PROVIDERS ABOUT SAFETY CONCERNS
WITH
GETINGE/MAQUET VASOVIEW HEMOPRO EVH SYSTEMS AND SUPPLY CONCERN
FOR EVH DEVICES- WEBSITE
* FDA: WORKING WITH MANUFACTURER TO EVALUATE REPORTS OF
SILICONE
DETACHMENT WITH VASOVIEW HEMOPRO 2 (VH-4000 AND VH-4001) DEVICES
* FDA: IDENTIFIED RECALL FOR VASOVIEW HEMOPRO 1.5 DEVICES AS
A
CLASS I RECALL
* FDA: GETINGE/MAQUET RECEIVED 18 COMPLAINTS FOR HEMOPRO 1.5
DEVICES BETWEEN APRIL 1-JULY 31
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Getinge publ AB
See all newsBrief: CEO Buys SEK 4.7 Million Of Getinge Shares
Johnson & Johnson defeats heart-pump patent claims in US trial (updated)
Johnson & Johnson defeats heart-pump patent claims in US trial
Brief: Getinge's Subsidiary Maquet Cardiovascular Receives Adverse Jury Trial Verdict In Patent Infringement Dispute With Abiomed In U.S.
Getinge lags profit estimates as uncertainty curbs investments in medical equipment